Re:Hydroxychloroquine Covid-19: a multinational registry ana...
by Khelavaster on Friday May 22, 2020 @03:22PM
(#23275876)
> Hayashi pointed out that the key piece of evidence underpinning the previous Cochrane review’s conclusion--that Tamiflu reduced the risk of secondary complications such as pneumonia--was based on a manufacturer-authored, pooled analysis of 10 manufacturer-funded trials
Everything needed for FDA approval.
> no convincing trial evidence
It just sounds like Tamiflu efficacy studies to date haven't been thorough enough to be convincing.
Everything needed for FDA approval.
> no convincing trial evidence
It just sounds like Tamiflu efficacy studies to date haven't been thorough enough to be convincing.